Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camizestrant and Atirmociclib in ER+/HER2- Advanced Breast Cancer
NCT07427394Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of camizestrant, atirmociclib in breast cancer, sponsored by AstraZeneca. Started May 2026; status: recruiting.
02
Drugs
camizestrantatirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07427394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07427394.